http://investing.businessweek.com/research/stocks/private/snapshot.asp?privcapId=11461617
Pacific Biosciences, Inc.
Pacific Biosciences, Inc. operates as a biotechnology company in North America. The company develops a transformative single-molecule (SMRT) DNA sequencing platform, which enables the observation of natural DNA synthesis by a DNA polymerase as it occurs; simplifies the resequencing of complex genomes; and the characterization of structural variation, including insertions, deletions, and rearrangements. Its products include SMRT chip, which enables the observation of individual fluorophores against a dense background of labeled nucleotides by maintaining a signal-to-noise ratio; and Phospholinked nucleotides that produce a natural DNA strand through DNA synthesis. Its product applications include de novo sequencing and resequencing. Pacific Biosciences, Inc. was formerly known as Nanofluidics, Inc. The company was founded in 2004 and is based in Menlo Park, California.
Pacific Biosciences, Inc. Appoints Susan K. Barnes as Chief Financial Officer
03/3/2010
Pacific Biosciences, Inc. announced the appointment of Susan K. Barnes as Chief Financial Officer. Susan Barnes has nearly 30 years experience in senior financial management. From 1997 to 2005, she was Senior Vice President, Finance and Chief Financial Officer of Intuitive Surgical, Inc. Ms. Barnes started at Intuitive Surgical as its first full-time finance person during the company's early development stages, and retired when it was a public company with a market capitalization of more than $3 billion and positive cash flow of more than $50 million a year.
10 Institutions Purchases Pacific Biosciences, Inc.’s Single Molecule Real Time (SMRT(TM)) DNA Sequencing System
02/23/2010
Pacific Biosciences, Inc. announced the 10 institutions that have purchased its Single Molecule Real Time (SMRT(TM)) DNA sequencing system as part of the company's early access program in North America. The North American early access customers are: Baylor College of Medicine, the Broad Institute of MIT and Harvard, Cold Spring Harbor Laboratory, the U.S. Department of Energy Joint Genome Institute, The Genome Center at Washington University, Monsanto Company, the National Cancer Institute/SAIC-Frederick, the National Center for Genome Resources, the Ontario Institute for Cancer Research, and Stanford University. The first shipments to members of the early access program will begin in the first half of 2010. Pacific Biosciences is also planning early access programs for Europe and Asia later this year. Pacific Biosciences will use the 10-site early access program as a systematic way to garner feedback on the SMRT system and to ensure that it is fully prepared to scale its operations to meet expected demand at commercial launch in the second half of 2010. The company also announced its third-party program to provide complimentary solutions for the SMRT system, including sample prep consumables and informatics tools.
Pacific Biosciences, Inc. Presents at Sixth Annual Translational Medicine, Feb-05-2010
02/1/2010
Pacific Biosciences, Inc. Presents at Sixth Annual Translational Medicine, Feb-05-2010. Venue: Moscone North Convention Center, San Francisco, California, United States. Speakers: Eric E. Schadt, Chief Scientific Officer.
BIOTECHNOLOGY